Plasminogen activator inhibitor 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Plasminogen activator inhibitor 1 shows clinical signal disease relevance led by Alzheimer disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P05121. Start with Alzheimer disease, then reuse UniProt P05121 as the stable protein anchor across project notes and exports.
Start with Alzheimer disease, then reuse UniProt P05121 as the stable protein anchor across project notes and exports.
Plasminogen activator inhibitor 1 shows clinical signal disease relevance led by Alzheimer disease. 1 linked drug remains visible in the same block.
Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include ALEPLASININ. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPlasminogen activator inhibitor 1
Review this target as Plasminogen activator inhibitor 1, mapped to UniProt P05121. Sequence length is 402 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Plasminogen activator inhibitor 1 as ChEMBL target CHEMBL3475, mapped to UniProt P05121. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Plasminogen activator inhibitor 1 is the right protein anchor across sources, using UniProt P05121 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Alzheimer disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Plasminogen activator inhibitor 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P05121 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Plasminogen activator inhibitor 1 |
| UniProt Accession | P05121 |
| Component Type | Protein |
| Sequence Length | 402 aa |
Plasminogen activator inhibitor 1
Review this target as Plasminogen activator inhibitor 1, mapped to UniProt P05121. Sequence length is 402 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Plasminogen activator inhibitor 1 shows clinical signal disease relevance led by Alzheimer disease.
Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include ALEPLASININ. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3669202 | 8.51 | Kd | 3.1 | Preclinical |
| CHEMBL3669203 | 8.28 | Kd | 5.3 | Preclinical |
| CHEMBL112242 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL1224764 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL207014 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL3669202 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL377052 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL419935 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL425946 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL2087114 | 7.64 | Kd | 23.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 46 | 283 | 5.6 |
| cell-based format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-free format | 1 | 5 | 7.4 |